NCT02581423View on ClinicalTrials.gov

A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Colorectal Cancer
Interventions
DRUG

Capecitabine

Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.

Trial Locations (6)

1431

Sofia

1527

Sofia

2700

Blagoevgrad

5000

Veliko Tarnovo

7000

Rousse

Unknown

Shumen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02581423 - A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer | Biotech Hunter | Biotech Hunter